Document is current
Any future updates will be listed below
-
Authors
Boddicker, Nicholas J. https://orcid.org/0000-0002-6784-2072
Shanafelt, Tait D.
Parikh, Sameer A. https://orcid.org/0000-0002-3221-7314
Rabe, Kari G. https://orcid.org/0000-0002-7313-1875
Griffin, Rosalie https://orcid.org/0009-0007-5721-3727
Norman, Aaron D. https://orcid.org/0000-0002-4208-2708
Yao, Yuan
Tian, Shulan
Ma, Tao
O’Brien, Daniel R.
Vallejo, Bryan A.
Hoel, Mingma S.
Lehman, Stacey J.
Olson, Janet E. https://orcid.org/0000-0003-4944-7789
Hampel, Paul J. https://orcid.org/0000-0003-1292-3024
Braggio, Esteban https://orcid.org/0000-0003-3860-4830
Patnaik, Mrinal M. https://orcid.org/0000-0001-6998-662X
Cerhan, James R. https://orcid.org/0000-0002-7482-178X
Vachon, Celine M. https://orcid.org/0000-0002-1962-9322
Hanson, Curtis A.
Slager, Susan L. https://orcid.org/0000-0002-5173-4712
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA235026)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA258465)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG58266)
- License Information
-
More Information
Article History
Received: 15 June 2025
Revised: 2 September 2025
Accepted: 23 September 2025
First Online: 6 November 2025
Competing interests
: SAP: Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria have been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, Amgen, MingSight Pharmaceuticals, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie for Sameer A. Parikh’s participation in consulting activities/advisory board meetings. PJH: Research funding has been provided to the institution from AstraZeneca and BeiGene for clinical studies in which PJH is a principal investigator. Honoraria have been provided to the institution from AbbVie For PJH participation in consulting activities/advisory board meetings. TDS: Reports receiving grant support from Pharmacyclics, AbbVie, Genentech, and holding a patent (US14/292,075) on green tea extract epigallocatechin gallate in combination with chemotherapy for chronic lymphocytic leukemia. MP: Research funding from Kura Oncology, Stem Line Pharmaceuticals, Polaris, Epigenetic, and Solutherapeutics. Serves on the advisory board for SOBI, AstraZeneca, and GSK.
